Skip to Content

CheckMate 649’s Four-Year Survival Data on Chemo + Nivolumab for Gastric & Esophageal Cancer

The four-year survival data from the CheckMate 649 study, revealed at the ASCO GI meeting, demonstrates the survival benefits of combining chemotherapy with nivolumab. This pivotal research supports the recommendation that this combination therapy should be adopted as the new standard of care for treating gastric and esophageal cancers.

Kohei Shitara

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top